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Abstract
High hopes have been pinned on regenerative medicine strategies in order to prevent the progression of 
cartilage damage to osteoarthritis, particularly by autologous chondrocyte implantation (ACI). The loss 
of chondrocyte phenotype during in vitro monolayer expansion, a necessary step to obtain sufficient cell 
numbers, may be a key limitation in ACI. In this study, it was determined whether a shorter monolayer 
expansion approach could improve chondrogenic differentiation. The effects of two supplement types, 
foetal bovine serum (FBS) and Stemulate™ (a commercial source of human platelet lysate), on the expansion 
and re-differentiation potential of human chondrocytes, isolated from five individuals, were compared. 
Chondrocytes were expanded with 10 % FBS or 10 % Stemulate™. Pellets were cultured for 28 d in 
chondrogenic differentiation medium and assessed for the presence of cartilage matrix molecules and genes 
associated with chondrogenicity. Stemulate™ significantly enhanced the proliferation rate [average population 
doubling times: FBS, 25.07 ± 6.98 d (standard error of the mean, SEM) vs. Stemulate™, 13.10 ± 2.57 d (SEM)]. 
Sulphated glycosaminoglycans (sGAG), total collagen and qRT-PCR analyses of cartilage genes showed that 
FBS-expanded chondrocytes demonstrated significantly better chondrogenic capacity than Stemulate™-
expanded chondrocytes. Histologically, FBS-expanded chondrocyte pellets appeared to be more stable, with 
a more intense staining for toluidine blue, indicating a greater chondrogenic capacity. Although Stemulate™ 
positively influenced chondrocyte proliferation, it had a negative effect on chondrogenic differentiation 
potential. This suggested that, in the treatment of cartilage defects, Stemulate™ might not be the ideal 
supplement for expanding chondrocytes (which maintained a chondrocyte phenotype) and, hence, for cell 
therapies (including ACI).
Keywords: Human platelet lysate, Stemulate™, foetal bovine serum, human chondrocytes, cartilage, 
autologous chondrocyte implantation.
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Introduction
Damaged articular cartilage has a limited potential 
for healing and untreated cartilage defects often 
progress to osteoarthritis (OA) (Davies-Tuck et al., 
2008). Regenerative medicine strategies have been 
formulated to meet the challenge of preventing 
progression to OA; one such strategy is autologous 
chondrocyte implantation (ACI) (Nawaz et al., 2014). 
ACI has evolved over 20 years, but chondrocytes are 
still the preferred cell choice. In brief, autologous 
chondrocytes are harvested by arthroscopy from 
a lesser weight-bearing area of the joint, expanded 
in monolayer culture and re-implanted into the 
damaged area under a natural or synthetic membrane 
by an open joint surgical procedure (Brittberg et al., 
1994). Robert Jones & Agnes Hunt (RJAH) Hospital, 
Oswestry and others report a high percentage of 
good to excellent clinical results (Bhosale et al., 2009; 
Henderson et al., 2003). Although there is limited 
long-term follow-up data, especially from the 
modern methods of ACI, positive clinical results are 
beginning to emerge. Nawaz et al. (2014) report a 78 % 
at 5 years and 51 % at 10 years ACI graft survival 
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for 827 patients. A robust economic model, based 
on a systematic review, indicates that ACI is cost-
effective as compared with alternative procedures, 
providing long-lasting improvements in symptoms 
and eventually reducing the need for knee joint 
replacements (Mistry et al., 2017; Web Ref. 1). Overall, 
the consensus is that ACI is more effective if used 
early following a cartilage injury and if it is the first 
attempt at a surgical intervention. Further refinement 
of ACI will ultimately enhance clinical outcomes and 
this, in part, is one of the goals of the present study.
 To obtain sufficient cell numbers from small 
cartilage biopsies, the chondrocytes need to undergo 
in vitro expansion. The loss of chondrocyte phenotype, 
known as de-differentiation (Benya and Shaffer, 
1982; Schnabel et al., 2002), during in vitro expansion 
on tissue culture plastic is a key limitation of ACI. 
During de-differentiation, chondrocytes lose their 
rounded morphology and decrease gene and protein 
expression of collagen II and aggrecan, both key 
components of the articular cartilage extracellular 
matrix (ECM). Consequently, de-differentiation 
decreases the capacity of re-implanted chondrocytes 
to regenerate functional cartilage (Schulze-Tanzil, 
2009). At the RJAH Hospital, Oswestry, most of the 
freshly isolated chondrocytes usually undergo two 
passages because de-differentiation is known to 
occur in as few as three passages (Kang et al., 2007). 
Nevertheless, further minimising the conditions that 
promote chondrocyte de-differentiation may improve 
ACI.
 Current standard protocols for chondrocyte 
expansion involve growth medium supplemented 
with foetal bovine serum (FBS), human autologous 
serum (AS) or serum-free medium. While FBS is used 
traditionally for in vitro chondrocyte expansion, an 
increase in demand and limited stocks are constantly 
increasing its price. FBS is a poorly defined mixture 
of components that can contain endotoxins, prion 
and viral proteins (Jochems et al., 2002; Selvaggi et 
al., 1997; van der Valk et al., 2010). Current good 
manufacturing practice (GMP) guidelines state 
that animal products should be replaced by human 
alternatives, wherever possible, for translating 
into cell therapies (Giancola et al., 2012; Unger et 
al., 2008; World Health Organisation, 1992; World 
Health Organization, 1991). Human AS would seem 
the ideal solution, but patient-to-patient variability 
can negatively impact upon key parameters, such 
as chondrocyte growth and quality (Harrison et al., 
2000). Further, a relatively large volume of blood is 
required to perform chondrocyte expansion for ACI 
and this can be uncomfortable for the patients. A 
preferred alternative is defined serum-free growth 
media, but these media are supplemented with 
expensive growth factors that need to be replenished 
regularly during chondrocyte expansion. Given the 
issues described, other options are needed.
 The use of platelet lysate for in vitro cell proliferation 
began in the 1980s (Choi et al., 1980). Doucet et al. 
(2005) describe the preparation and application 
of human platelet lysate (HPL) for expanding 
mesenchymal stem cells. Further studies show both 
autologous and allogeneic HPL to be superior to FBS 
in enhancing cell proliferation (Burnouf et al., 2016; 
Hildner et al., 2015; Hofbauer et al., 2014; Kim et al., 
2015; Trojahn Kølle et al., 2013). HPL eliminates the 
risk of cross-species contamination, solves standing 
ethical considerations and meets the GMP guidelines. 
In addition, it contains high levels of growth factors 
and cytokines and a range of vitamins and minerals 
that are also present in FBS and human AS (Hemeda 
et al., 2014; Shih and Burnouf, 2015). HPL is created 
from large donor pools, reducing the variability 
observed with other serum types. However, there are 
limitations to HPL use, including the potential risk of 
contamination with human viruses, some of which 
are screened for, including HIV. Many studies show 
that 5-10 % (v/v) HPL is superior to 10 % (v/v) FBS 
in supporting cell expansion in several different cell 
types (King and Buchwald, 1984; Mojica-Henshaw 
et al., 2013; Muraglia et al., 2014; Reinisch et al., 2007; 
Trojahn Kølle et al., 2013; Witzeneder et al., 2013). 
A HPL concentration of 10 % (v/v) supports cell 
proliferation at levels comparable to FBS (Burnouf 
et al., 2016; Hemeda et al., 2014; Hildner et al., 2015; 
Hofbauer et al., 2014). Only a handful of studies 
use HPL as an in vitro tool for human chondrocyte 
expansion (Gaissmaier et al., 2005; Hildner et al., 
2015; Moreira Teixeira et al., 2012; Muraglia et al., 
2014; Spreafico et al., 2009). Even fewer investigate 
the recovery of chondrocyte phenotype, known as 
re-differentiation, in 3-dimensional (3D) culture when 
the HPL is excluded from the re-differentiation media 
(Hildner et al., 2015). With ACI therapy in mind, it is 
important to ensure that the expanded chondrocytes 
have a chance to recover their chondrogenic 
phenotype in 3D culture without further exposure 
to relatively high levels of platelet-derived growth 
factors, which increase cell proliferation.
 Stemulate™ (Cook Regentec, Indianapolis, IN, 
USA), a commercially available source of HPL, is 
prepared according to GMP guidelines, using large 
donor pools from accredited blood centres. Given 
that Stemulate™ is used to expand a range of cell 
types, including adipose-derived mesenchymal stem 
cells (MSCs) and bone-marrow MSCs, it could be 
an alternative supplement to increase chondrocyte 
proliferation for cartilage cell therapy (Badowski et 
al., 2017; Juhl et al., 2016; Mangum et al., 2017; Riis 
et al., 2016; Søndergaard et al., 2017). Stemulate™ 
could reduce time in monolayer culture and reduce 
exposure to tissue-culture plastic, which in turn could 
reduce the risk of de-differentiation. The aim of the 
current work was to determine whether Stemulate™ 
could be a suitable alternative serum supplement to 
FBS for human chondrocyte expansion by assessing 
growth characteristics and cell morphology. Further, 
by using chondrogenic medium for both sets of 
chondrogenic pellets during re-differentiation in 
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3D culture, the aim was to assess the recovery of 
chondrocytes and determine their ability to produce 
ECM.
Materials and Methods
Chondrocyte isolation and monolayer expansion
Fully informed consent was obtained from five 
individuals undergoing total knee replacement 
surgery at RJAH Hospital, Oswestry, with ethical 
approval (11/NW/0875). Full depth cartilage was 
removed from macroscopically normal areas of the 
femoral condyle from three male and two female 
individuals with a mean age of 67 years (range: 
55-75 years). Chondrocytes were isolated following 
an established protocol (Harrison et al., 2000). 
Briefly, 100-300 mg of cartilage tissue were placed 
into 10 mL Dulbecco’s modified Eagle’s medium 
(DMEM)/F12 (11330-057; Gibco) containing 0.03 mg/
mL deoxyribonuclease I (D4263; Sigma-Aldrich) 
and 0.83 mg/mL type XI collagenase (C9407; Sigma-
Aldrich). Digestion was performed for 16 h in a T25 
tissue culture flask (Sarstedt) at 37 °C and 5 % CO2. 
The digest was filtered through a 0.2 µm cell strainer 
and chondrocytes were pelleted at 750 ×g for 10 min. 
After that > 98 % cell viability was verified using 
trypan blue (T8154; Sigma-Aldrich), the chondrocytes 
were plated into T175 tissue-culture flasks at a density 
of 5 × 104 cells/cm2 in DMEM/F12 supplemented with 
0.5 % (w/v) penicillin-streptomycin-amphotericin 
(17-745E; Lonza), 0.5 % (w/v) ascorbate (A4544; 
Sigma-Aldrich) and either 10 % (v/v) FBS (10500-
064; Gibco) or 10 % (v/v) Stemulate™ (PL-SP-100; 
Cook Regentec). Media were replenished three 
times weekly. Once 80 % confluency was reached, 
the chondrocytes were passaged and re-seeded at 
a density of 5 × 104 cells/cm2. Chondrocytes were 
cultured in monolayer until the end of passage 2.
Growth kinetics during monolayer expansion
To assess growth kinetics during monolayer 
expansion, population doubling times (PDTs) were 
recorded at each passage and calculated using the 
following formula (McAteer and Davis, 2002):
Re-differentiation in 3D pellet culture in 
chondrogenic medium
At the end of passage 2, the chondrocytes were 
detached and re-suspended in chondrogenic re-
differentiation medium optimised from the Johnstone 
method (Johnstone et al., 1998), comprising DMEM/
F12 supplemented with 1 % (v/v) FBS, 1 % (v/v) non-
essential amino acids (11140-035; Gibco), 1 % (v/v) 
L-glutamine (G7513; Sigma-Aldrich), 0.5 % (v/v) 
penicillin-streptomycin-amphotericin (17-745E; 
Lonza), 0.5 % (w/v) ascorbate (A4544; Sigma-
Aldrich), 1 % (v/v) insulin-transferrin-selenium 
(51500-056; Gibco), 20 ng/mL transforming growth 
factor-β1 (100-21; Peprotech), 10 nM dexamethasone 
(D4902; Sigma-Aldrich) and 3.2 µg/mL L-proline 
(P0380; Sigma-Aldrich). The chondrocytes (2.5 × 105 
cells) were transferred to 1.5 mL Eppendorf® tubes 
and centrifuged at 750 ×g for 7 min, to create 
spherical pellets. Pellets were cultured in 500 µL of 
chondrogenic medium. Medium was replenished 
twice weekly.
Pellet processing for analyses
Pellets were assessed at day 0, 7, 14, 21 and 28. For 
biochemical assays, pellets (n = 5) were digested 
in 1 mg/mL proteinase K (25530-015; Ambion) in 
100 mM ammonium acetate (09691; Sigma-Aldrich) 
for 2 h at 60 °C. Proteinase K was inactivated 
for 5 min at 100 °C and samples were stored at 
− 20 °C. For histology, pellets (n = 4) were placed 
onto Whatman filter paper (Whatman, Kent, UK), 
snap frozen in liquid-nitrogen-cooled n-hexane 
and stored at − 80 °C. For gene expression analysis, 
pellets (n = 3) were prepared for RNA extraction by 
homogenisation in 350 µL RLT lysis buffer containing 
1 % (v/v) β-mercaptoethanol (M6250; Sigma-Aldrich) 
using a 21 G needle and syringe (1053393; QIAGEN) 
and stored at − 80 °C.
Pellet cell number
Cell number was determined using the PicoGreen® 
fluorescent DNA quantification kit (17916; Invitrogen), 
with lambda DNA as standard (1 ng/mL-1 µg/mL). 
Duplicate samples and standards were transferred 
to a 96-well plate and fluorescence was read at 
an excitation of 480 nm and emission of 520 nm 
using a FLUOstar Omega microplate reader (BMG, 
Ortenberg, Germany). Cell number was calculated 
using the widely reported value of 7.7 pg of DNA 
per chondrocyte (Kim et al., 1988).
Total sGAG content in the pellets
T h e  t o t a l  s G A G  wa s  d e t e r m i n e d  u s i n g 
1,9-dimethylmethylene blue (DMMB) (Farndale et 
al., 1986). All reagents were procured from Sigma-
Aldrich. Chondroitin sulphate A from bovine trachea 
(C9819) was used as standard (0-200 µg/mL). In 
brief, 4 mg DMMB (341088) were diluted in 250 mL 
distilled water containing 0.76 g glycine (G5516) and 
0.595 g sodium chloride (S5886) to a final pH of 3.0. 
Duplicate samples and standards were transferred to 
a 96-well plate and mixed with 200 µL of DMMB dye. 
Absorbance was read at 530 nm using a FLUOstar 
Omega microplate reader (BMG).
Total collagen content in the pellets
The total collagen content was determined by a 
hydroxyproline assay (Brown et al., 2001). All reagents 
were procured from Sigma-Aldrich. Hydroxyproline 
standards (0-0.1 µg/mL; H5,440-9) were prepared in 
distilled water. 100 µL of each sample were hydrolysed 
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in 100 µL of 10 M hydrochloric acid (19068) for 16 h at 
108 °C. On cooling, the samples were neutralised with 
800 µL of 1 M sodium hydroxide (S5881). Duplicate 
samples and standards were transferred to a 96-well 
plate. 100 µL of oxidation buffer [600 mL isopropyl 
alcohol, 330 mL distilled water, 390 mL citrate/
acetate buffer (1 L consists of 34 g sodium hydroxide 
(S5881), 34 g citric acid monohydrate (C7129) and 
120 g sodium acetate trihydrate (32318-M)), pH 6.0] 
were used as a negative control. Oxidation solution 
[100 µL; 300 mg chloramine T (402869) dissolved in 
50 mL oxidation buffer] was added to all samples 
and standards. The plate was incubated at room 
temperature for 5 min. Ehrlich’s reagent [100 µL; 6 g 
p-dimethylaminobenzaldehyde (156477) dissolved in 
a mixture of 16 mL of 50 % perchloric acid (244252) 
and 52 mL of isopropyl alcohol] was added to each 
well and, then, the plate was sealed and incubated 
in a 60 °C water bath for 45 min. Absorbance was 
measured at 570 nm using a FLUOstar Omega 
microplate reader (BMG) and total collagen was 
calculated using the widely reported multiplication 
factor of 7 (Sims et al., 2000).
qRT-PCR to assess gene expression in the pellets
mRNA was extracted using the QIAGEN RNeasy 
mini kit as per manufacturer’s instructions. mRNA 
was reverse-transcribed in a Progene thermocycler 
(Techne, Staffordshire, UK) using a high-capacity 
cDNA reverse transcription kit (4368814; Applied 
Biosystems) following the manufacturer’s 
instructions. qRT-PCR was performed on three 
pellet replicates (from each patient) to determine 
gene expression relative to two reference genes, 
according to published guidelines (Bustin et al., 2009): 
hypoxanthine-guanine phosphoribosyltransferase-1 
(HPRT1 human; RT00059066) (Foldager et al., 2009; 
Rushton et al., 2014) and TATA box-binding protein 
(TBP; QT00000721) (Foldager et al., 2009; Pombo-
Suarez et al., 2008) were selected based on low co-
efficiencies of variance across both supplement types 
(data not shown). Several genes (Table 1) were chosen 
to determine the chondrogenic phenotype after re-
differentiation. All genes, including reference genes, 
were procured from QIAGEN. Gene expression 
was measured relative to the reference genes 
and normalised to the cell number. Relative 
gene expression profiles were determined by the 
comparative CT method (Schmittgen and Livak, 2008).
Histology of the frozen pellets
The frozen pellets were mounted onto pre-cooled 
chucks with optimal cutting temperature (OCT) 
compound (00.090.112; Sakura Finetek, Zoeterwoude, 
the Netherlands). All stains were procured from 
VWR International. 7 µm-thick sections were 
collected onto poly-L-lysine pre-coated slides (MBC-
0102-54A; Cell Path, Newtown, UK) and stained 
with haematoxylin (350604T) and eosin (34197) 
or toluidine blue (340774Y), according to Roberts 
and Menage (2004). Sections were imaged by light 
microscopy (Leitz, Wetzlar, Leica Microsystems 
GmbH, Stuttgart, Germany) using ×6.3, ×25 and 
×40 objective lenses. Images were captured using 
Table 1. Genes used in qPCR analysis. Genes were selected to determine the chondrogenic phenotype 
of the cells and if the chondrocytes had de-differentiated to a hypertrophic state.
Gene Official name and species Amplicon length Entrez ID
Reference genes
HPRT1 Hypoxanthine phosphoribosyltransferase 1 (human) 130 (NM_000194) 3251
TBP TATA box binding protein (human) 132 (NM_001172085)132 (NM_003194) 6908
Chondrogenic markers
ACAN Aggrecan (human)
62 (NM_001135)
62 (NM_013227)
62 (XM_001131727)
62 (XM_001131734)
62 (XM_00670419)
176
COL2A1 Collagen type 2 alpha 1 (human) 95 (NM_001844) /
95 (XM_006719242)
1280
SOX9 SRY (sex determining region Y)-box 9 (human) 112 (NM_000346) 6662
De-differentiation markers
COL1A1 Collagen type 1 alpha 1 (human)
118 (NM_000088)
118 (NM_003257058)
118 (XM_005257059)
118 (XM_006721703)
1277
Hypertrophic markers
ALK1/ACVRL1 Activin A receptor type II-like 1 (human) 74 (NM_000020) 94
COL10A1 Collagen type 10 alpha 1 (human) 91 (NM_000493) 1300
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a DS-Fi1 camera and analysed with NIS-Elements 
BR imaging software (Nikon). Images were white-
balanced using Photoshop Elements (Adobe). To 
semi-quantify the toluidine blue staining intensity, 
four central images of each pellet were randomly 
selected and the integrated density was determined 
using ImageJ Software (NIH) according to the 
published methodology (Jensen, 2013; Owida et al., 
2017; Prasad and Prabhu, 2012).
Statistical analyses
All independent outcomes (PDTs, cell number, 
sGAG, total collagen, qPCR and staining intensity), 
patient variability and differences between the two 
supplement types over the time course were analysed 
using a multilevel model. Supplement type and 
time points were considered fixed variables and the 
patient was considered a random variable (random 
intercept). All qPCR data were log-transformed 
before the analysis, to make the data fit a normal 
distribution.
 Cell number, sGAG and total collagen data (n ≥ 4 
per time point per patient, 5 patients in total) were 
expressed as mean ± standard error of the mean 
(SEM). Gene expression data (n = 3 per time point 
per patient, 5 patients in total) were shown as a 
box plot, with the box representing the second and 
third quartiles, the horizontal line inside the box 
representing the median and the whiskers either 
side of the box representing the lower and upper 
quartiles. All statistical analyses were performed with 
SPSS statistical software (version 24; IBM) and, for all 
analyses, p < 0.05 was deemed to denote statistical 
significance.
Results
Stemulate™ positively influenced proliferation of 
chondrocytes in monolayer culture
For all 5 patients, the chondrocytes expanded in 
Stemulate™ (mean PDT: 13.10 ± 2.57 d) proliferated 
quicker than the chondrocytes expanded in FBS (mean 
PDT: 25.07 ± 6.98 d, p = 0.050). Patient variability was 
considered not statistically significant (p = 0.48) 
in affecting the PDT. Both sets of chondrocytes 
underwent less than 2 absolute population doublings 
throughout passages 1, 2 and 3 (Fig. 1). No statistically 
significant difference was measured in population 
doublings between the two sera supplements 
(p = 0.527) or at any passage (p = 0.50). Patient 
variability was considered not statistically significant 
(p = 0.445) in affecting population doublings.
 Chondrocytes expanded in both FBS and 
Stemulate™ were seeded at an equal cell density 
upon chondrocyte isolation, after which both sets of 
chondrocytes showed a significant increase in cell 
number over time (p < 0.001; Fig. 2). Chondrocytes 
expanded in Stemulate™ demonstrated a significantly 
larger increase in cell number as compared to 
chondrocytes expanded in FBS (p = 0.014). Patient 
variability was considered not statistically significant 
(p = 0.296) in affecting cell number in monolayer.
 Fig. 3 shows the morphology of the human 
chondrocytes (day 4 of each culture) in the presence 
of either Stemulate™ or FBS during passage 0, 1 
and 2. For Stemulate™-expanded chondrocytes, 
markedly more chondrocytes were present and they 
appeared to cluster together at all passages. For both 
supplement types, chondrocytes appeared elongated 
and flattened, with little difference in their cell shape 
at all passages.
Stemulate™ negatively influenced the re-
differentiation potential of chondrocytes in 3D 
pellet culture
To investigate whether the removal of Stemulate™ at 
the end of chondrocyte monolayer expansion resulted 
in delayed ECM production in 3D pellet culture, a 
28 d time course was performed. 3D pellets were 
assessed for cell number (Fig. 4), total sGAG (Fig. 5), 
total collagen (Fig. 6) and gene expression by q-PCR 
(Fig. 7).
 For both supplement types, cell number (Fig. 
4) remained consistent throughout the time course 
(p = 0.84). This was expected since the 3D pellet 
conformation should enable the chondrocytes to 
recover their morphology and prevent further 
Fig.  1.  Absolute population doublings of 
chondrocytes expanded in FBS and Stemulate™ 
sera at each of the three passages. Data are 
presented as mean ± SEM (n = 5).
Fig. 2. Cell number during monolayer expansion 
of chondrocytes in FBS- and Stemulate™-
supplemented sera. Cell number was calculated 
from cell counts during chondrocyte (seeded at 
an equal cell density) isolation and across three 
passages. Data are presented as mean ± SEM (n = 5).
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Fig.  3 .  Representative images of 
chondrocytes expanded in culture media 
supplemented with 10 % (a,c,e) FBS 
and (b,d,f) Stemulate™ at passage 0-2 
(P 0-P 2). Images were taken at day 4 of 
each passage to allow the chondrocytes 
to adhere. All images were taken using 
the Nikon TS100 light microscope and 
×20 magnification. Images were acquired 
using the IPLab 3.2.6 software. Scale bars: 
10 µm.
proliferation. Total sGAG (Fig. 5) and total collagen 
(Fig. 6) production were normalised to cell number. 
Chondrocytes expanded in both supplement types 
demonstrated a steady and significant increase in 
sGAG production across all time points (p < 0.001) 
(Fig. 5). sGAG concentration was higher in FBS as 
compared to Stemulate™ across all time points 
(p = 0.009), as determined by multi-level modelling. 
A significant sharp increase in sGAG concentration at 
day 14 was observed for FBS-expanded chondrocytes 
(p < 0.001), with a slight levelling off in sGAG 
production at day 28 for both supplements. No 
evidence of variability among individual patients at 
any time point was detected (p = 0.60) (Fig. 5).
 Collagen production demonstrated a significant 
interaction between treatment and time (p = 0.001) 
(Fig. 6). Both supplement types showed a similar 
pattern of relatively steady levels until a sharp 
increase between day 21 and 28, with levels 
being significantly higher in FBS as compared to 
Stemulate™ (p = 0.001). Again, there was no evidence 
of variability among individual patients at any time 
point (p = 0.26) (Fig. 6).
 RT-qPCR was performed at day 0, 21 and 28; 
relative gene expression profiles were determined by 
the comparative CT method (Schmittgen and Livak, 
2008) and normalised to the cell number. Expression 
of COL1A1, COL10A1 or ALK1 was not detected in 
either supplement type. For the key chondrogenic 
markers ACAN, COL2A1 and SOX9 there were 
striking differences between gene expression profiles 
in each supplement. ACAN expression increased 
over the time course in both supplements (p < 0.001 
for time), but was significantly higher in FBS- than 
Stemulate™-expanded pellets at day 0 (p < 0.001) 
and day 21 (p = 0.013). COL2A1 expression was 
significantly higher in FBS- than in Stemulate™-
expanded pellets at day 0 (p = 0.033) and day 21 
(p = 0.034). FBS-expanded pellets demonstrated a 
significantly higher expression of SOX9 at day 21 
(p = 0.012) and day 28 (p = 0.002) when compared with 
Stemulate™-expanded pellets. There was no evidence 
of variability among patients for ACAN (p = 0.48) and 
COL2A1 expression (p = 0.33) or for a general change 
in COL2A1 (p = 0.20) and SOX9 expression (p = 0.15) 
over time (Fig. 7).
FBS improved the quality of the ECM produced 
in 3D pellet culture
Frozen chondrogenic pellets were sectioned (7 µm) 
and stained with haematoxylin and eosin (H&E) 
or toluidine blue to visualise general morphology 
and proteoglycan distribution, respectively (Fig. 8). 
At day 7, chondrocytes expanded in Stemulate™ 
appeared to form less stable and more fragile pellets 
when compared with chondrocytes expanded in 
FBS. Morphological differences seemed apparent 
in the cells occupying the periphery of the pellets. 
These cells appeared to be more fibroblastic in 
pellets created from the Stemulate™-expanded 
chondrocytes as compared to those created from FBS-
expanded chondrocytes (Fig. 8). In both supplement 
types, there was a trend for the staining intensity of 
the chondrogenic pellets to increase over time. Pellets 
from FBS-expanded chondrocytes demonstrated 
an increase in metachromasia. This increase was 
quantitated using ImageJ software (Fig. 9), to confirm 
that, at day 21, FBS-expanded chondrocytes had 
a significantly more intense staining as compared 
to Stemulate™-expanded chondrocytes (p = 0.045). 
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Again, there was no evidence of variability among 
patients in staining intensity (p = 0.48).
Discussion
This study focused on two sera supplements and 
their effects on human chondrocyte proliferation 
and the chondrocytes’ subsequent recovery using 
standard chondrogenic differentiation protocols. 
To our knowledge, this is the only study providing 
a detailed analysis of ECM production from 5 
individuals. However, it was not possible to compare 
AS among donors because the existing ethically 
approved protocol does not allow taking a sufficient 
volume of blood to provide sera for monolayer in 
vitro expansion to the end of passage 2, representing 
a limitation of the study. Another limitation was 
that only chondrocytes obtained from total knee 
replacement were evaluated. Therefore, caution must 
be used when interpreting these data as compared 
with chondrocytes sourced from patients undergoing 
ACI, as the patient populations for these treatments 
differ (for example, patients undergoing ACI tend to 
be younger than those undergoing joint replacement 
surgery). Despite these limitations, four key points 
were demonstrated. First, Stemulate™ increased 
chondrocyte proliferation when compared to FBS. 
This result was not surprising since several studies 
report that HPL increases cell proliferation in many 
cell types (Crespo-Diaz et al., 2011; Hemeda et al., 
2014; Hildner et al., 2015; Luttenberger et al., 2000; 
Mojica-Henshaw et al., 2013). Second, monolayer 
expansion of human chondrocytes in Stemulate™ 
negatively influenced the stability of the 3D pellets 
as compared to expansion in FBS: these chondrogenic 
pellets disintegrated easily when sectioned, slightly 
losing the pellet form – especially in the cells 
occupying the periphery, which appeared to be 
more fibroblastic. Third, total sGAG synthesis 
by Stemulate™-expanded chondrocytes lagged 
behind the FBS-expanded ones. Fourth, expansion 
in Stemulate™ negatively influenced chondrogenic 
gene expression in 3D pellets as compared to FBS.
 There is clear evidence to confirm that 5-10  % 
(v/v) HPL is more effective in supporting monolayer 
expansion of human MSCs than both FBS and AS at 
the same concentration range (Bieback et al., 2009; 
Juhl et al., 2016; Trojahn Kølle et al., 2013). Further, 
both Bieback et al. (2009) and Juhl et al. (2016) report 
that HPL supported long term monolayer expansion 
whilst still maintaining the MSCs phenotype and their 
differentiation potential. Given these positive data, 
herein it was established that Stemulate™ was better 
than FBS at increasing chondrocyte proliferation 
in monolayer culture. No published studies have 
used Stemulate™ for chondrocyte expansion, 
but increased proliferation is shown when using 
derivatives of HPL. Spreafico et al. (2009) compare 
the effects of platelet rich plasma (PRP), platelet 
poor plasma (PPP) and FBS on human chondrocytes 
over a 20 d cell proliferation time course, with 
PRP resulting the most stimulatory in terms of 
chondrocyte proliferation. Hildner et al. (2015) report 
that 5  %-10  % HPL significantly increase human 
chondrocyte proliferation as compared to FBS. From 
Fig. 4. Cell number in chondrogenic pellets 
created from chondrocytes expanded in 
FBS- and Stemulate™-supplemented sera 
over a 28 d time course. Data are presented 
as mean ± SEM for day 0-21 (n = 5) and up 
to day 28 (n = 3).
Fig. 5. sGAG production per cell in 
chondrogenic pellets created from 
chondrocytes expanded in FBS- and 
Stemulate™-supplmented sera over a 28 d 
time course. Data are presented as mean 
± SEM for day 0-21 (n = 5) and up to day 
28 (n = 3). a denotes statistical significance 
for time. b denotes statistical significance 
for supplement type. c denotes statistical 
significance at day 14.
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these studies and the current, it is evident that HPL 
increases the proliferation of human chondrocytes in 
monolayer culture.
 In the current study, no morphological differences 
were observed in human chondrocytes that were 
monolayer-expanded in Stemulate™ or FBS. No other 
published study has investigated morphological 
differences between human chondrocytes expanded 
in HPL or FBS. However, Trojahn-Kølle et al. (2013) 
report morphological differences in monolayer-
expanded MSCs, appearing smaller and less 
spindle-like when cultured in HPL as compared 
with FBS. In the current study, 3D pellets from 
human chondrocytes expanded in monolayer in 
Stemulate™ created more fragile, less compact 
pellets as compared to those expanded in FBS, as 
seen by qualitative histological assessment. These 
chondrogenic pellets disintegrated easily, losing 
their pellet form, when prepared for histological 
analysis, resulting in a more difficult sectioning of 
the Stemulate™-expanded pellets at day 7. This 
was not assessed quantitatively but was a consistent 
observation throughout the study.
 Very few studies use HPL with human chondrocytes 
and even fewer investigate sGAG production 
in 3D pellets. Following a published 3D pellet 
chondrogenic differentiation protocol (Johnstone 
et al., 1998; Pittenger, 1999), it was demonstrated 
that FBS-expanded human chondrocytes generated 
significantly more sGAG than Stemulate™-expanded 
human chondrocytes across a 4-week time course. 
These results were opposite to the findings of 
Hildner et al. (2015), who report that HPL-expanded 
chondrocytes produce more sGAG than FBS-
expanded chondrocytes in micromass pellets 
created from the same chondrogenic differentiation 
Fig. 6. Total collagen production per 
cell in chondrogenic pellets created 
from chondrocytes expanded in 
FBS- and Stemulate™-supplemented 
sera over a 28 d time course. Data 
are presented as mean ± SEM for day 
0-21 (n = 5) and up to day 28 (n = 3). 
a denotes statistical significance for 
time. b denotes statistical significance 
at day 28.
Fig. 7. Box and whisker plot of gene expression profiles of the chondrogenic pellets created from chondrocytes 
expanded in FBS- and Stemulate™-supplemented sera. Data are expressed relative to the reference genes, 
obtained from 5 patients using 3 experimental pellet replicates per patient, and determined by using the 
comparative CT method. a denotes statistical significance for time. b denotes statistical significance for 
aggrecan expression at day 0. c denotes statistical significance for aggrecan expression between supplement 
types at day 21. d denotes statistical significance for collagen II expression between supplement types at day 
0. e denotes statistical significance for collagen II expression between supplement types at day 21. f denotes 
statistical significance for SOX9 expression between supplement types at day 21. g denotes statistical 
significance for SOX9 expression between supplement types at day 28.
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protocol used in this study, over a 5-week period. 
After a 5-week culture period, a more intense sGAG 
staining is observed in HPL-expanded human 
chondrogenic pellets, compared to FBS pellets 
(Hildner et al., 2015). These differences could be 
due to the supplement types, since Stemulate™ was 
used in the current study, whereas Hildner et al. 
(2015) use a HPL generated in their own laboratory 
from PRP obtained from 36 expired thrombocyte 
concentrates produced at a transfusion blood centre. 
5 batches of HPL are characterised by Quantikine 
ELISA for these experiments, but no further details 
on the characterisation are given (Hildner et al., 2015). 
Furthermore, in the current study, the 3D pellets were 
cultured in chondrogenic medium without HPL, 
whereas Hildner et al. (2015) add HPL into 3D pellet 
cultures.
 In contrast to sGAG, total collagen production 
levels were found to be quite low throughout the 
3D pellet culture 4-week time course. Despite this, 
collagen production by Stemulate™-expanded 
human chondrocytes appeared to lag behind FBS-
expanded human chondrocytes. Gaissmaier et al. 
(2005) also observe that HPL-expanded chondrocytes 
seeded into 3D alginate beads produce low levels of 
collagen over a shorter time course of 14 d.
 In the 3D pellet cultures, genes that determine 
chondrocyte differentiation state were investigated. 
De-differentiation was investigated through the 
relative expression of COL1A1 (Benya et al., 1978; 
Brew et al., 2010) and hypertrophy through the 
relative expression of COL10A1 (Caron et al., 2012; 
Dell’Accio et al., 2001) and ALK1 (Blaney Davidson et 
al., 2009; Dell’Accio et al., 2001). ALK1 is up-regulated 
during monolayer expansion, due to a loss of in 
vivo cartilage formation potential, and is associated 
with irreversible chondrocyte de-differentiation 
(Blaney Davidson et al., 2007; Blaney Davidson et 
al., 2009; Dell’Accio et al., 2001). None of these genes 
were detected in 3D pellets derived from either 
Stemulate™- or FBS-expanded human chondrocytes, 
suggesting that the human chondrocytes had not 
undergone de-differentiation or hypertrophy. In 
addition, chondrogenic capacity was assessed 
through the relative expression of COL2A1, ACAN 
and SOX9. COL2A1 and ACAN are necessary for 
ECM formation and the transcription factor SOX9 
regulates chondrocyte proliferation, chondrogenesis 
and transition to a non-hypertrophic state. Expression 
of COL2A1 and ACAN declines following prolonged 
monolayer culture, particularly after passage 4 
(Schulze-Tanzil et al., 2002). For both these ECM 
markers, an increase was found across the 4-week 
time course. However, a much larger increase in 
relative gene expression was expected, especially 
by day 28, as this is found in similar published 
studies (Hildner et al., 2015). An explanation 
could be that nutrient saturation was approached 
Fig. 8. Representative histological images from the centre of the FBS- and Stemulate™-expanded 
chondrogenic pellets across the 28 d time course. (a-f) Pellets stained with haematoxylin and eosin (H&E) 
to assess overall morphology. (g-l) Pellets stained with toluidine blue to assess proteoglycan content. Insert 
images are higher-powered images of the regions marked with a solid line. Scale bars: 100 µm.
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before day 28. Overall, SOX9 gene expression was 
more striking in FBS 3D pellets when compared 
to Stemulate™, indicating that the FBS-expanded 
human chondrocytes recovered chondrogenic 
potential more quickly. Taken together, these 
findings suggest that Stemulate™ caused a delay in 
the recovery of chondrogenic phenotype following 
monolayer expansion. It would have been interesting 
to perform q-PCR on the monolayer chondrocytes 
prior to seeding into pellets and to compare the 
relative gene expression of the chondrocytes 
before and during pellet culture. This would have 
determined how the relative gene expression levels 
would have changed following chondrogenic 
differentiation. However, the chondrocytes used 
were primary isolated chondrocytes and monolayer-
expanded up to passage 2, which limited cell number 
and prohibited the use of q-PCR analysis on the 
monolayer chondrocytes.
 The multilevel modelling analyses performed 
allowed the comparison of the treatments over the 
time course and the exploration of the impact of 
patient variability (Hox, 2010; Vaughn, 2008). One 
of the limitations of the study was that cartilage 
was obtained from joints that were potentially 
osteoarthritic. OA is classified as a whole-joint 
disease and, although the cartilage was taken 
from macroscopically normal areas, chondrocytes 
could still have had a sub-chondrogenic phenotype 
upon differentiation. A previous study shows that 
osteoarthritic chondrocytes express higher levels 
of ALK1 (Blaney Davidson et al., 2009), but ALK1 
expression was not detected in the monolayer-
expanded chondrocytes. Patient variability was 
expected, but no statistical evidence was found 
for a patient-specific influence on any of the 
measured outcomes. Clearly more work needs to 
be done, but the current work demonstrated that 
although Stemulate™ led to rapid proliferation, it 
affected the re-differentiation potential of human 
chondrocytes. These findings demonstrated that 
Stemulate™ induced a sub-chondrogenic phenotype 
upon differentiation or enhanced monolayer-
induced chondrocyte de-differentiation and reduced 
chondrogenic capacity. Therefore, it should be used 
with caution when expanding chondrocytes for 
clinical use.
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